Alex Toker received a BSc from King's College, University of London, UK in 1987 and a PhD from the National Institute for Medical Research, London, UK in 1991. He conducted his post-doctoral research in the laboratory of Prof. Lewis Cantley, first in the Department of Physiology, Tufts University School of Medicine, then in the Department of Cell Biology, Harvard Medical School and Division of Signal Transduction, Beth Israel Deaconess Medical Center. His first faculty appointment was as Staff Scientist at the Boston Biomedical Research Institute in 1997, where he was promoted to Principal Scientist in 1999. In 2000 he joined the faculty of Beth Israel Deaconess Medical Center and Harvard Medical School as an Assistant Professor in the Department of Pathology. In 2003, he was promoted to Associate Professor and joined the faculty of the HMS PhD program in Biological and Biomedical Sciences. In 2010, he was promoted to Professor of Pathology at HMS. In 2014, he was appointed Chief of the Division of Signal Transduction in the Departments of Pathology and Medicine and Cancer Center at BIDMC

Other Activities:

1. •  Associate Editor, JBC
   

2. •  Editorial Board, Molecular and Cellular Biology 
   

3. •  Member of Faculty of 1000

Alex Toker, PhD

Christian Dibble, PhD

Christian Dibble received his PhD from the Harvard School of Public Health in the laboratory of Brendan Manning. He was a post-doctoral fellow in the lab of Lewis Cantley at BIDMC/HMS, and his current research focuses on the PI 3-K and Akt  signaling pathway in cancer metabolism. Christian was promoted to Instructor in Pathology at HMS in 2014, and is a recipient of a K99 Howard Temin Pathway to Independence Award from the NCI.

Renee Geck

Renee Geck received her BS degree from the George Fox University, Oregon. Her research focuses on metabolic reprogramming and vulnerabilities in cancer.

Laura Ghisolfi received her PhD degree from the University of Milan, Italy, and  subsequently conducted post-doctoral research at Brigham and Women’s Hospital and BIDMC. Her research in the Toker lab focuses on metabolic reprogramming and vulnerabilities in cancer. Laura is a Senior Research Associate and Toker Lab manager.

Laura Ghisolfi, PhD

Hui Liu, PhD

Hui Liu received her PhD from MIT in the laboratory of Richard Hynes. She was a post-doctoral fellow in the lab of Lewis Cantley and Gerburg Wulf at BIDMC/HMS, and her current research in the Toker lab focuses on the INPP4B tumor suppressor in cancer. Hui is a recipient of a 2014 Susan G Komen fellowship award.

KangKang Yang

Emily Cohen, PhD

Emily Cohen her PhD from Yale University in the laboratory of Dan DiMaio. Her current research in the Toker lab focuses on resistance mechanisms to cancer therapies and cancer stem cells, and on metabolic reprogramming in the tumor vasculature. Her research is supported by a T32 NHLBI training award.